Tegaserod
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Heartburn
Conditions
Heartburn, Dyspepsia
Trial Timeline
Apr 1, 2005 → Sep 1, 2006
NCT ID
NCT00171457About Tegaserod
Tegaserod is a phase 3 stage product being developed by Novartis for Heartburn. The current trial status is completed. This product is registered under clinical trial identifier NCT00171457. Target conditions include Heartburn, Dyspepsia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00511771 | Pre-clinical | Completed |
| NCT00414024 | Phase 3 | Terminated |
| NCT00390975 | Approved | Terminated |
| NCT00399659 | Phase 3 | Terminated |
| NCT00365820 | Phase 2/3 | Terminated |
| NCT00348634 | Approved | Terminated |
| NCT00171457 | Phase 3 | Completed |
| NCT00171470 | Phase 3 | Completed |
| NCT00139568 | Phase 3 | Completed |
| NCT00563758 | Pre-clinical | Terminated |
| NCT00563615 | Pre-clinical | UNKNOWN |
| NCT00171431 | Phase 3 | Terminated |
| NCT00232037 | Phase 3 | Completed |
| NCT00232102 | Phase 3 | Completed |
| NCT00232089 | Phase 3 | Completed |
| NCT00142974 | Phase 2 | Terminated |
| NCT00142987 | Approved | Completed |
| NCT00149877 | Approved | Completed |
| NCT00141089 | Phase 3 | Completed |
| NCT00171483 | Phase 3 | Completed |
Competing Products
20 competing products in Heartburn